Tier 2 — strong

The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study

Eman Mohamed Elmokadem, Dina Khaled Abou El Fadl, Ahmed M Bassiouny, Maisa Mohamed Abd Elkhalik Mahmoud, Mohammed Samy, Nouran Omar El Said
Drug design, development and therapy 2025 19:6009-6024

Bibliography

PubMed
PMID 40687903
PubMed Central
PMC12273731
DOI
10.2147/DDDT.S526188
Funding
Reported funding/support: financial The authors received no financial support for the research and/or authorship of this article.
Competing interests
Reported disclosure: The authors declare that they have no competing interests.

Study snapshot

DesignRandomized double-blind placebo-controlled perioperative trial
ModelHuman intervention research
Sample80 elective cesarean patients; 40 per group
InterventionSingle oral quercetin 500 mg dose or placebo 1 hour before surgery
DurationAcute perioperative dosing; pain assessed through 24 hours
EndpointsSymptoms and quality of life; Events and survival

What the study showed, in plain terms

Published in 2025, this source examined inflammation and clinical symptoms. Design: Randomized double-blind placebo-controlled perioperative trial. Sample/model: 80 elective cesarean patients; 40 per group. The exposure or intervention was Single oral quercetin 500 mg dose or placebo 1 hour before surgery. Follow-up or treatment period: Acute perioperative dosing; pain assessed through 24 hours.

Pain scores were lower and the first analgesic request occurred later with quercetin. Total morphine use and hospital stay did not differ.

Monitored perioperative setting. This does not establish routine pregnancy, breastfeeding or unsupervised surgical-supplement safety.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Inflammation: CRP, Pain and Human Trials. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pain scores were lower and the first analgesic request occurred later with quercetin.
  • Total morphine use and hospital stay did not differ.
  • The recorded outcome domains were Symptoms and quality of life; Events and survival.
  • The result applies to the tested exposure: Single oral quercetin 500 mg dose or placebo 1 hour before surgery; Acute perioperative dosing; pain assessed through 24 hours.

What this study can and cannot tell us

  • Monitored perioperative setting. This does not establish routine pregnancy, breastfeeding or unsupervised surgical-supplement safety.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
Zohreh Sajadi Hezaveh et al. · Complementary therapies in medicine · 2019
Tier 2
Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I-III degree hemorroidal disease: a double-blind multicenter prospective comparative study
Italo Corsale et al. · International journal of colorectal disease · 2018
Tier 2
The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial
Fatemeh Javadi et al. · Journal of the American College of Nutrition · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology